12.12.2018 • NewsCristalElaine BurridgeTronox

US Judge Rules Against Tronox-Cristal Merger

US Judge Rules Against Tronox-Cristal Merger (c) Tronox
US Judge Rules Against Tronox-Cristal Merger (c) Tronox

In yet another blow for the proposed Tronox-Cristal titanium dioxide (TiO2) merger, a US Federal Trade Commission (FTC) administration law judge has ruled that the deal would substantially lessen competition for the sale of chloride-based pigment.

Although Tronox said it was disappointed, the decision does now mean that the US producer can work directly with the FTC and seek Commissioners’ approval to the proposed remedy, something it was not allowed to do prior to the ruling.

The previously proposed remedy comprises Tronox selling its complex and associated assets at Ashtabula, Ohio in the US to Ineos. Tronox announced earlier this month that it wanted to sell the site for $700 million to Ineos, a potential new entrant into the TiO2 market.

“As the owner of Ashtabula, Ineos would be a strong competitor with the expertise to increase output and efficiency, bringing a new energy to the TiO2 industry in a way that would benefit consumers,” said Jeffry Quin, president and CEO of Tronox.

The two plants and related assets at Ashtabula would be held separate during an interim period while the proposed divestment is pending. In addition, Tronox and Cristal’s North American TiO2 production would continue to be operated independently, meaning there would be no increase in industry concentration. This, said Tronox, would eliminate the risks of anticompetitive effects that the FTC alleged in its original complaint.

Tronox has already received approval for the deal from eight other regulators, including the European Commission.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.